Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma

Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim

Clin Mol Hepatol. 2024;30(3):360-374. Published online March 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0042

View: 1588 Download: 195 Crossref: 1

Editorial

Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma

Ji Eun Han, Hyo Jung Cho

Clin Mol Hepatol. 2024;30(2):160-163. Published online February 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0141

View: 1898 Download: 49

Original Article

Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B

Hyo Jung Cho, Soon Sun Kim, Seun Joo Ahn, Joo Han Park, Dong Joon Kim, Young Bae Kim, Sung Won Cho, Jae Youn Cheong

Clin Mol Hepatol. 2014;20(4):347-354. Published online December 24, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.4.347

View: 8556 Download: 124 Web of Science: 16 Crossref: 15

Association between apolipoprotein E genotype, chronic liver disease, and hepatitis B virus

Seun Joo Ahn, Dong Kyu Kim, Soon Sun Kim, Chang Bum Bae, Hyo Jung Cho, Han Gyeol Kim, Young Jip Kim, Joo Ho Lee, Hyo Jin Lee, Mi Yeon Lee, Kee Bum Kim, Jin Hee Cho, Sung Won Cho, Jae Youn Cheong

Clin Mol Hepatol. 2012;18(3):295-301. Published online September 25, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.3.295

View: 8460 Download: 71 Crossref: 17

Correspondence

Correspondence on Editorial regarding “Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: a gateway to personalized medicine”

Su Bin Lim, Hyo Jung Cho

Received May 16, 2024 Accepted May 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0368 [Accepted]

PDF

View: 358 Download: 20

Viewed By 5504	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5404	MAFLD: How is it different from NAFLD?
Viewed By 5214	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5094	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4725	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Author :

Author index